Gilead inks non-exclusive licensing pacts with 5 generic drug-makers
Category: #health  | By Mateen Dalal  | Date: 2020-05-13 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Gilead inks non-exclusive licensing pacts with 5 generic drug-makers

Gilead Sciences, an American biopharmaceutical company, has recently inked non-exclusive licensing pacts with 5 India- and Pakistan-based generic drug-makers. These licensing agreements have been made to increase the supply of remdesivir, Gilead’s experimental COVID-19 treatment.

The licensing pacts will enable companies, namely Ferozsons Laboratories Ltd., Mylan NV, Hetero Labs Ltd., Cipla Ltd., and Jubilant Life Sciences Ltd., to manufacture and sell the drug in 127 countries. Gilead stated that these countries consist of low-income, lower-middle income, upper-middle as well as high-income populations. South Africa, Pakistan, North Korea, India, and Afghanistan are among the countries that the company will allow remdesivir production in. The company further added that the licensees or companies will set the prices for their generic products.

The licenses are reportedly royalty-free until the WHO (World Health Organization) declares the termination of the public health emergency posed by COVID-19 pandemic, or the development of a vaccine or other products that are approved to prevent or treat COVID-19 disease. This antiviral drug produced by Gilead received emergency use authorization from the U.S. Food & Drug Administration earlier this month to treat patients that are infected with the coronavirus.

Rising focus on this drug, due to the unavailability of other approved COVID-19 treatment (a respiratory disease caused by coronavirus), has been observed. The company is being analyzed closely on its distribution and pricing of the limited supply of this antiviral drug. Gilead previously reported that it was negotiating with various generic drug-makers in Pakistan and India regarding the long-term licenses to offer the drug in developing countries. It has also negotiated on offering the technology that support the drug production.

The coronavirus pandemic has reportedly claimed the lives of around 286,000 people globally. To address and combat the spread of this virus, several drug-makers are accelerating the development of a viable vaccine or treatment candidate.

Source credit:

https://zeenews.india.com/world/gilead-ties-up-with-generic-drugmakers-in-india-pakistan-for-coronavirus-covid-19-drug-supply-2283098.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

UK’s Health Secretary announces 10-year plan to tackle dementia

UK’s Health Secretary announces 10-year plan to tackle dementia

By Mateen Dalal

The UK Health and Social Care Secretary, Sajid Javid, has reportedly announced a novel 10-year plan to effectively tackle dementia and to increase funding in research to get a better understanding of neurodegenerative diseases. As per sources, at ...

Starbucks to cover abortion related travel expenses for workers

Starbucks to cover abortion related travel expenses for workers

By Mateen Dalal

Starbucks has reportedly announced that it would start covering all eligible travel expenditures for the workers seeking gender-affirming surgical procedures or abortions. As per reports, the coffee conglomerate has joined Apple, Amazon, Salesforc...

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

By Mateen Dalal

The on-going conflict between Russia and Ukraine has adversely affected the fish and chips industry in the United Kingdom, driving the closure of centuries-old shops, sharp price hikes, and change in menus. The National Federation of Fish Friers (...